Drug Trial Radar · NCT05337553
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
269
Actual
Start
Jul 6, 2022
Primary completion
Sep 25, 2024
Study completion Dec 2027
Sponsor
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will study the efficacy and safety of taldefgrobep alfa as an adjunctive therapy for participants who are already taking a stable dose of nusinersen and/or risdiplam and/or have a history of onasemnogene abeparvovec, compared to placebo.
Conditions
- Spinal Muscular Atrophy
- Neuromuscular Diseases
- SMA
Interventions
taldefgrobep alfaDrug
DB Phase: 35 mg/50 mg weekly subcutaneous injection
PlaceboDrug
DB Phase: matching placebo 35 mg/50 mg weekly subcutaneous injection
taldefgrobep alfaDrug
Extension Phase: 35 mg/50 mg weekly subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of taldefgrobep alfa compared to placebo in change in the 32 item Motor Function Measure (MFM-32) total scoreTime frame: Baseline to Week 48
Locations
53 sites in 9 countries. Site status is shown where the registry gives one.
Phoenix Children's
Phoenix, Arizona
UCSD & Rady Children's
La Jolla, California
Children's Hospital of Los Angeles
Los Angeles, California
UCSF Benioff Children's Hospital, Medical Center
San Francisco, California
Children's Hospital Colorado
Aurora, Colorado
UF Health, Shands Hospital
Gainesville, Florida
Rare Disease Research
Atlanta, Georgia
Northwestern University - Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Indiana University -Riley Research
Indianapolis, Indiana
University of Iowa
Iowa City, Iowa
University of Kansas Medical Center
Fairway, Kansas
Boston Children's Hospital - Harvard
Boston, Massachusetts
BSHS Office of Research
Grand Rapids, Michigan
Washington University in St. Louis
St Louis, Missouri
Columbia University Medical Center
New York, New York
Stony Brook University Hospital
Stony Brook, New York
Duke University Medicine
Durham, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Nationwide Children's Hospital
Columbus, Ohio
Penn State College of Medicine
Hershey, Pennsylvania
CHOP Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
UT Pediatric Neurosciences/Dell Children's Medical Center
Austin, Texas
Neurology Rare Disease Center
Denton, Texas
Cook Children's Hospital
Fort Worth, Texas
University of Virginia Children's Hospital
Charlottesville, Virginia
Children's Hospital of The King's Daughters
Norfolk, Virginia
MultiCare Institute of Research and Innovation
Tacoma, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
University Hospital Antwerp
Edegem, Belgium
University Hospital Ghent
Ghent, Belgium
University Hospital Leuven
Leuven, Belgium
University Hospital Brno - Dept. of Pediatric Neurology
Brno, Czechia
Motol University Hospital
Prague, Czechia
University Hospital Essen (Public-Law Institution) - Dept. of Pediatrics I
Essen, Germany
University Hospital Freiburg, Center For Children and Adolescent Medicine, Dept. of Neuropediatrics and Muscle Disorders
Freiburg im Breisgau, Germany
Dr. Von Haunersches Children'S Hospital - Lmu Munich
Munich, Germany
Irccs Institute of Neurological Sciences of Bologna - Bellaria Hospital
Bologna, Italy
Nemo-Brescia Clinical Center For Neuromuscular Diseases
Gussago, Italy
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.